Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 1995, for OXIS International, Inc. (Note: The request metadata listed "GT Biopharma," but the filing text identifies the registrant as OXIS International, Inc.). The company is a biotechnology firm focused on developing therapeutics for diseases associated with free radical damage. The financial statements are prepared on a going concern basis, contingent upon the company's ability to secure additional financing.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1995 | Nine Months Ended Sep 30, 1995 |
|---|---|---|
| Total Revenues | $1,098,000 | $4,310,000 |
| Net Loss | $(4,831,000) | $(7,050,000) |
| Net Loss Per Share | $(0.41) | $(0.68) |
| Cash and Cash Equivalents | $1,008,000 (Sep 30, 1995) | $1,008,000 (Sep 30, 1995) |
| Working Capital Deficit | $(656,000) | $(656,000) |
| Total Debt (Current + Long-term) | $1,707,000 | $1,707,000 |
| Operating Cash Flow | Filing text does not provide a clear value for the quarter | $(4,059,000) |
Note: The Net Loss includes a one-time charge of $3,329,000 for purchased in-process technology related to the acquisition of Therox Pharmaceuticals, Inc.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues for the nine months ended September 30, 1995, increased to $4,310,000 from $1,741,000 in the prior year period. This 148% increase was driven by the inclusion of acquired businesses (OXIS S.A. and IBC) and increased sales of diagnostic assays and Palosein.
- Expense Increases: Research and development expenses rose significantly to $3,044,000 (nine months 1995) from $813,000 (nine months 1994), primarily due to costs associated with acquired pharmaceutical technologies. Selling, general, and administrative expenses also more than doubled to $2,318,000.
- Acquisition Impact: The company acquired Therox Pharmaceuticals in July 1995, resulting in a $3,329,000 charge for in-process technology. This charge significantly impacted the net loss for the period.
- Liquidity Position: The working capital deficit improved from $1,046,000 at December 31, 1994, to $656,000 at September 30, 1995, aided by $3,538,000 in proceeds from stock issuances.
Guidance, Outlook, and Risks
- Capital Needs: Management explicitly states the company must raise additional capital during the remainder of 1995 to continue operations. An investment banking firm has been engaged to raise up to $3,000,000, but no assurances are given.
- Going Concern Risk: If additional capital is not raised, the company intends to curtail operations by reducing personnel, facility costs, and R&D efforts. Failure to do so could force the company into reorganization, bankruptcy, or insolvency proceedings.
- Revenue Risks: Sales of bovine superoxide dismutase (bSOD) to Sanofi Winthrop (35% of 1994 revenues) are not expected to continue following a failed Phase III trial of the drug DISMUTEC. Additionally, regulatory actions in Spain and other European countries pose risks to future bSOD sales.
- Outlook: The company expects to continue reporting losses in the near term as expenses exceed revenues. Future success depends on developing business alliances with larger biotechnology or pharmaceutical companies.
Investor Verification Checklist
- Capital Raise Status: Verify if the company has successfully secured the additional funding required to operate through the end of 1995.
- Sanofi Winthrop Relationship: Confirm the status of the bSOD supply agreement and the impact of the failed DISMUTEC trial on future revenue streams.
- Regulatory Environment: Monitor regulatory developments in Spain and other European countries regarding the company's bSOD products.
- Therox Integration: Assess the progress of the Therox Pharmaceuticals acquisition and the commercialization potential of its free radical therapeutics.
- Debt Obligations: Review the terms of the $1,366,000 in notes payable and the $250,000 inventory note to ensure compliance with repayment schedules.